Pregnancy outcome after first trimester exposure to domperidone—An observational cohort study
| Autor: | Kunihiko Takahashi, Ken Nakajima, Atsuko Murashima, Kayoko Hishinuma, Yoshiyuki Saito, Takahide Arimoto, Masahiro Hayashi, Ikuko Yokoo, Ritsuko Yamane, Mikako Goto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Metoclopramide pregnancy outcomes Logistic regression Cohort Studies 03 medical and health sciences 0302 clinical medicine Pregnancy Medicine Humans 030219 obstetrics & reproductive medicine observational cohort study business.industry Obstetrics Incidence (epidemiology) Pregnancy Outcome Obstetrics and Gynecology Odds ratio Original Articles medicine.disease Confidence interval Domperidone Pregnancy Trimester First 030220 oncology & carcinogenesis Original Article Female teratogenicity business first trimester Cohort study medicine.drug |
| Zdroj: | The Journal of Obstetrics and Gynaecology Research |
| ISSN: | 1447-0756 1341-8076 |
| Popis: | Aim To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control. Methods Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The incidence of major malformation was calculated among infants born to women taking domperidone (n = 519), nonteratogenic drugs (control, n = 1673), or metoclopramide (reference, n = 241) during the first trimester of pregnancy. Using the control group as reference, the crude odds ratio (OR) of the incidence of major malformation in the domperidone and metoclopramide groups was calculated using univariable logistic regression analysis. Adjusted OR was also calculated using multivariable logistic regression analysis adjusted for various other factors. Results The incidence of major malformation was 2.9% (14/485, 95% confidence interval [CI]: 1.6–4.8) in the domperidone group, 1.7% (27/1554, 95%CI: 1.1–2.5) in the control group, and 3.6% (8/224, 95%CI: 1.6–6.9) in the metoclopramide group. The adjusted multivariable logistic regression analysis showed no significant difference in incidence between the control and domperidone groups (adjusted OR: 1.86 [95%CI: 0.73–4.70], p = 0.191) or between the control and metoclopramide groups (adjusted OR: 2.20 [95%CI: 0.69–6.98], p = 0.183). Conclusions This observational cohort study showed that domperidone exposure during the first trimester was not associated with increased risk of major malformation in infants. These results may help alleviate the anxiety of patients who took domperidone during pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text